On 5-6 April, 18 stakeholders from the precision medicine field met in Valencia (Spain) to discuss responsible innovation in their industry sector. The workshop was hosted by IMEGEN, a biomedical biotechnological company that offer genetics test based on clinical utility (also a member of the SMART-map consortium).
Representatives from Spanish and multinational companies (i.e. Kanteron, Eugenomic, GoodGut, Agilent, DREAMgenics, Bemygene) were invited to discuss responsible innovation with members from academia, research, civil society and communication.
According to Mari Carmen Álvarez, one of the organisers of the workshop, participants groups were quite different from those that attended the Danish Industrial Dialogue on the same topic. In Aarhus, the discussion was more focused on the technical aspects, such as biobanks, data sharing and data management, while in Valencia they talked more about communications and marketing skills. Participants also debated on how to get across these RRI objectives to the society.
As a general conclusion, she explains, there is a lot of work to do in order to implement the RRI principles in these non-technical areas.